zWe're a mall ni . In Pharma, q picall ha e one grq p doing he em con g ra ion v i h t er accep ance e ing and implemen a ion and ano her grq p doing he ac al b ild of each rial in q r ca e, q r mall eam ha o do i all. The Medida a Profe ional Ser ice eam v a incredibl t ppor i e d ring he enablemen pha e and implemen a ion proce , and i e-learning and cer i ca ion helped t o learn abq he pla form and q ickl increa e ef cienc and op imi e q r clinical rial proce e .

S a a C d e

After receiving detailed training on the platform and completing the implementation in six months, the SCTU team began conducting their clinical trials on the Medidata platform. Designed as a uni□ed data platform, Rave EDC

zB ing a em - ha bo h he pharmace ical ind r recogni e , and he reg la or accep - o e ec e high q ali clinical rial , q r mi ion o bring be er rea men o pa ien fa er can, l ima el , be reali ed.

zAdop ing Medida a' pla form ha allov ed for more people o engage v i h he da a and for o broaden he e of he da a. We' e hif ed o he idea ha e er one ov n he da a.

S a a C d e
Head f Ci cai Da a
Ma a e e , S a
Ci cai T ai U i

Prioritizing Support in the Pandemic

More recently, as the world was gripped by the COVID-19 pandemic, Medidata also supported SCTU on its COVID-19 studies. The AGILE platform, a collaboration between the University of Liverpool, the Southampton CTU, and other external partners, is a new type of platform designed for pandemic drug testing and was launched specifically to test new COVID-19 treatments. The platform represents the first of its kind for infectious diseases, capable of testing multiple potential treatments in parallel and speeding up testing by pooling control data across patient groups. This allows new treatments to go through testing in a matter of months rather than years, while always maintaining a high level of safety.

Medidata's Rave EDC and Rave RTSM (randomization and trial supply management) were selected to support this program, and due to the recent increase in need for more hygienic processes, Medidata eConsent was also included to consent the patients electronically using an iPad as opposed to traditional paper forms. These three solutions required a rapid response and significantly reduced lead time to meet the demands of these COVID-19 studies, in the hopes of getting a treatment to market as soon as possible.

"When it came to building trials in Rave EDC for the AGILE clinical trial platform, Medidata's turnaround was brilliant and the service and support our team received was excellent. The Medidata team worked swiftly, were incredibly responsive and reliable, and the turnaround process helped us to get the clinical trial platform up and running quickly," Condie concluded.

See full protocol of the AGILE-ACCORD trial **here**, as well as the AGILE website **here**.

> "When it came to building trials in Rave EDC for the AGILE clinical trial platform, Medidata's turnaround was brilliant and the service and support our team received was excellent. The Medidata team worked swiftly, were incredibly responsive and reliable, and the turnaround process helped us to get the clinical trial platform up and running quickly,"
>
> Sarah Candie
> Head of Clinical Data Management, Senior Clinical Trials Unit